Press Releases Year None20222021202020192018 Sep 06, 2022 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Aug 08, 2022 Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 04, 2022 Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Jul 12, 2022 Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults Jun 02, 2022 Vaxcyte to Present at the Jefferies Healthcare Conference May 09, 2022 Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update May 03, 2022 Vaxcyte to Participate in Upcoming Investor Conferences in May Apr 05, 2022 Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 04, 2022 Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults Feb 28, 2022 Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Year None20222021202020192018 Sep 06, 2022 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Aug 08, 2022 Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 04, 2022 Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Jul 12, 2022 Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults Jun 02, 2022 Vaxcyte to Present at the Jefferies Healthcare Conference May 09, 2022 Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update May 03, 2022 Vaxcyte to Participate in Upcoming Investor Conferences in May Apr 05, 2022 Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 04, 2022 Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults Feb 28, 2022 Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
